Levothyroxine tapering
PreclinicalSmall molecule
Levothyroxine tapering is one of 9 small molecule programs targeting Hypothyroidism. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Hypothyroidism
#DrugCompanyPhaseTrials
1Synthroid
IInstitut Jerome Lejeune
Approved
Tricor
JJagotec
Approved
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Levothyroxin
BBerlin-Chemie AG Menarini Group
Phase 3
Armour Thyroid
AbbViePhase 3
Triostat
VViking Therapeutics, Inc.
Preclinical
Medication
NNYU Langone Health
Preclinical
Thyrotropin-Releasing Hormone
NNational Center for Research Resources (NCRR)
Preclinical
Levothyroxine tapering
SSeoul National University Bundang Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Levothyroxine tapering. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details